Purchase this article with an account.
R. A. Grigorian, A. Shah, S. Guo; Comparison of Loteprednol Etabonate 0.5% (Lotemax) to Prednisolone Acetate 1% (Falcon) for Inflammation Treatment Following Cataract Surgery. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1065.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The purpose of this study is to compare the efficacy, safety, and patient comfort of two topical corticosteroids, loteprednol etabonate 0.5% (Lotemax) and Prednisolone Acetate 1% (Falcon), for the treatment of postoperative inflammation after cataract surgery.
It was a randomized and double-blinded study. 20 patients were randomly assigned to Lotemax or Prednisolone Acetate. Follow up period was 4 weeks (patients being evaluated at 1 day, 1 week and 4 weeks, postoperatively). The main outcomes were measured including: 1) the efficacy of inflammation control (conjunctival hyperemia, corneal edema, aqueous cells, flare); 2) patient safety (visual acuity, intraocular pressure measured with Goldmann applanation tonometer); and 3) patient comfort.
In this study, patients from both groups achieved a similar resolution of postoperative inflammation. By the final visit, 60% of patients in the Lotemax group achieved significant resolution of inflammation compared to 50% of Prednisolone Acetate group. Lotemax appeared to have less effect on intraocular pressure elevation than Prednisolone Acetate. The average intraocular pressure on the final visit was 12 mmHg ±3 (range 8-16 mmHg) in the Lotemax group and 16 mmHg ±1 (range 12-20 mmHg) in the Prednisolone Acetate group.
Both Lotemax and Prednisolone Acetate were shown to have similar efficacy in controlling inflammation after uncomplicated cataract surgery. However, Lotemax showed less effect on intraocular pressure in these patients. Results of a larger series of patients is underway.
This PDF is available to Subscribers Only